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Summary.-The lymphocyte marker pattern of non-Hodgkin's lymphoma cells was
related to current concepts of lymphoma classification. In a series of28 lymphomas,
lymphocyte markers indicated that 2 were of histiocytic origin, 2 were unclassifiable,
none were derived from T cells and the remainder were B-cell neoplasms. The
immunoglobulin heavy chain associated with the B-cell tumours was y in one case,
af in one case but was ,- in the majority of cases, reflecting the predominance of this
heavy chain, together with 8 chains, on normal lymph node lymphocytes in man.
8 chains accompanied ,u chains on the tumour cells i!1 6/17 lymphomas in which anti-8
staining was performed. 8 chains were not found on any lymphomas other than well
differentiated diffuse lymphocytic types. There was evidence of a reduction in surface
immunoglobulin, Fcy and C3 receptors on undifferentiated lymphoma cells. T
lymphocytes of normal morphology were present in all lymphomas except one, and
were more numerous in follicular lymphomas than in diffuse tumours.
MANY lymphoproliferative diseases
involving peripheral blood and bone
marrow have been shown to originate
from distinct lymphocyte populations
defined by surface markers for T and B
lymphocytes (Seligmann, Preud'homme
and Brouet, 1973; Aisenberg, Bloch and
Long, 1973; Brouet, Flandrin and Selig-
mann, 1973). This kind of analysis has
more recently been applied to malignant
lymphomas, the solid tumours of the
immune system (Smith et al., 1973; Jaffe
et at., 1974; Huber et al., 1974; Aisenberg
and Long, 1975; Leech et al., 1975)
Brouet, Labaume and Seligmann, 1975).
The classification of these diseases is
currently receiving a critical re-analysis
in the light of current immunological
understanding of the function of the
components of the immune system
(Gerard-Marchant et al., 1974; Lukes and
Collins, 1975; Bennett et at., 1974). We
have investigated a group of untreated
non-Hodgkin's lymphomas using a panel
of lymphocyte markers, including surface
and intracellular immunoglobulin, Fcy
and C3 receptors and sheep erythrocyte
(E) receptors. The receptor pattern of
these lymphoma cells has been related
to normal lymphocyte maturation and to
current concepts of lymphoma classifica-
tion.
MATERIALS AND METHODS
Lymph nodes and peripheral blood.-Lym-
phoma tissue was obtained from biopsy
specimens taken from 27 untreated patients.
One patient (MID) had received treatment.
Uninvolved nodes from patients with carci-
noma, and nodes showing non-specific reac-
tive changes, were used as controls.
Biopsy tissue was finely minced and teased
in cold HEPES-buffered Eagles' medium
(HEPES-MEM, Biocult Laboratories, Pais-
ley), filtered through wire gauze and layered
over Ficoll-Triosil (Thorsby and Bratlie,
1970). Cells collected at the interface were
washed x3 by centrifugation (150 g, 10 min)
and the final pellet was resuspended at a
density of 2 x 106 cells/ml in HEPES-MEM
with 0.2% bovine serum albumin (BSA).
Viability was greater than 80% in all cases
except in one undifferentiated stem cell
lymphoma (see results).
Rosette tests.-Full details of cell prepara-
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rosette test, C3 rosette test and mixed anti-
globulin (MAG) reaction are described elsn-
where (Hallberg et al., 1973; Smith and
Haegert, 1974). In tlhle C3 rosette test, both
human R3 reagent (zymosan-treated whole
serum) and mouse serum (BALB/c or AKR)
were used as a source of complement with
control lymph nodes. In lymphoma cell
preparations, mouse serum (AKR) was used
consistently. Except for minor modifications,
the method of rosette formation has been
described fully elsewhere (Smith and Haegert,
1974; Payne et al., 1976). Rosettes were
examined as cytocentrifuge preparations,
thus enabling identification of tumour cells.
Immunofluorescence staining.-Polyvalent
rabbit antibodies to human immunoglobulins
(anti-Fab y) and specific rabbit or sheep
antisera to human ,u, 8, y, of heavy chains and
to K and A light chains were given by Professor
G. T. Stevenson of the Tenovus Research
Laboratory, Southampton. These fluorescein-
conjugated antisera were used to stain
directly viable cell suspensions for surface
immunoglobulins, and cell smears, fixed
overnight at -20°C in dry acetone, for intra-
cellular immunoglobulin. Controls of fluores-
cein-conjugated normal rabbit and/or sheep
immunoglobulins were included.
Both fluorescein-labelled cell suspensions
and fluorescein-labelled smear preparations
were examined using a Leitz Orthoplan
microscope fitted with an HBO-200 mercury-
vapour Ploem Epi-illuminator.
Serum and urine immunoglobulin analysis.
-Serum IgG, IgA and IgM levels were esti-
mated by nepholometry using a Technicon
autoanalyser. Serum electrophoresis was
performed routinely. Urine was concentrated
x 200 and analysed by electrophoresis. Para-
proteins and Bence-Jones protein were
characterized by immunoelectrophoresis.
RESULTS
Control lymph nodes
The mean values for T and B cells from
24 control (reactive) lymph nodes are
given in Table I, and the immuno-
fluorescent typing of surface immuno-
globulins from 8 control lymph nodes are
given in Table II. The results are expressed
as a percentage of total lymphoid cells
present.
TABLE I.-Mean Percentage of T and B
Cells in 24 Control (Reactive) Lymph
Nodes
T cells
Sheep
RBC
rosettes
Meaii 53*2*
s.d. 11-3
* Mean ±s.d.
B cells
FITC
C3 Fe y MAG surface
rosettes rosettes rosettes Ig
37-1 10-1 45-3 27-4
13-6 69 8-9 13-1
TABLE II. Percentage of Lymphocytes
Staining with Cla8ss-specific Antisera in
Control (Reactive) Lymnph Nodes
Patient
COL
GOS
HEA
POT
HUM
HYM
COX
MON
AMean
S.d.
Fab y
21
53
45
30
38
30
40
20
34-6
11 -5
V
2
10
0
2
15
0
0
13
5-3
6-3
of
3
0
0
1
5
0
2
0
1 *4
1 -8
/1L
18
37
33
25
38
18
18
17
25-5
9-1
8
19
39
40
19
40
28
2
21
26 0
13 -4
K
17
42
38
23
32
24
36
18
28-8
9.5
A
2
15
14
7
9
8
10
8
9-1
4-1
Lymiphoma nodes
The percentage of cells with T- and B-
cellmarkersin28non-Hodgkin'slymphoma
nodes are given in Table III. Each lym-
phomaisclassifiedaccordingtobothRappa-
port's (1966) and Lukes and Collins' (1975)
schemes. Two lymphomas were classified
as histiocytic. This was based in one case
(PUR) on ultrastructural characteristics,
namely the presence of lysosomes and
complex surface-membrane interdigita-
tions between adjacent cells, and in the
other (WUZ) on light-microscope mor-
phology and the ability to bind and phago-
cytose C3 indicatorred cells. Theremainder
were classified as lymphocytic lympho-
mas. T cells were present in all lymphomas
except ROD, and accounted for 4-76%
(mean 28%) of the extracted cell popula-
tion. These cells had the morphology of
small round lymphocytes. The presence
and size of the tumour cell population
was established by monotypic surface and/
or intracellular immunoglobulin staining
in 23 cases. In the majority of cases,
tumour cells could be readily identified
by morphological characteristics in Fc y,
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TABLE III.-T and B Cell Markers on Non-Hodgkin's Lymphoma Cells 0
Histology T B cells
r -A_ 8 cls _ -
Lukes Rosettes FITC antibody staining
&
Patient Rappaport* Collins E C3 Fc y MAG Fab y Brightness$ y a ju S K A
TUR WDDL Small 270 83 73 85 85 + + + O 0 86 0 85 0
non-
cleaved
non-FCC
GRA WDDL Small 14 nd 5 77 76 ++ 15 0 62 nd 68 0
non-
cleaved
non-FCC
KIN WDDL Small 18 80 96 nd 60 ++ 12 0 65 2 44 0
non-
cleaved
non-FCC
EVA WDDL Small 24 43 80 nd 78 ++ I 1 81 3 83 0
non-
cleaved
non-FCC
AND WDDL Small 6 30 70 nd 35 + 0 0 30 30 0 30
non-
cleaved
non-FCC
MID MWDDL Small 40 60 nd nd 61 + 0 0 20 10 37 0
non-
cleaved
non-FCC
HOL MWDDL Small 31 30 79 64 65 + 0 1 72 78 0 81
non-
cleaved
non-FCC
HER MWDDL Small 42 61 48 nd 58 + 0 0 33 24 58 0
non-
cleaved
non-FCC
WIL IDDL Small 9 87 63 93 84 + + + 0 1 91 31 96 2
non-
cleaved
non-FCC
ATW IDDL Small 9 63 63 nd 94 + 0 0 67 16 98 0
non-
cleaved
non-FCC
LAR WDNL Small- 60 nd nd nd 44 +++ 3 0 35 nd 32 0
cleaved
FCC
(nodular)
ATK WDNL Small- nd nd nd nd 61 + + + 0 0 65 nd 53 0
cleaved
FCC
(nodular)
SMA WDNL Small- 33 37 16 75 40 ++ 34 0 7 7 20 2
cleaved
FCC
(nodular)
THO WDNL Small- 67 43 16 35 41 ++ 6 9 38 1 34 2
cleaved
FCC
(nodular)
DIA WDNL Small- 20 57 22 87 82 ++ 2 1 74 9 7 46
cleaved
FCC
(nodular)
KNI WDDL Small- 12 48 32 88 57 +-+[+ 0 0 57 0 0 53
cleaved
FCC
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TABLE III.-continuted
Histology T
A_____ _____ ___ _ cells
Lukes
Patient Rappaport* Collins E
FEL
BEN
WOD
COL
ROD
OKU
SIR
SHE
STE
BAL
PUR
WDDL
MHLLN
UDDL
(Burkitt-like)
tJDDL
(Burkitt-like)
UDDL
(Burkitt-like)
UDDL
(Burkitt)
UDSL
UDSL
UDSL
Plasma-
cytoma
MHLLD
Small- 34
cleaved
FCC
(diffuse)
Large- 47
cleaved
FCC
(nodular)
Small 10
non-
cleaved
FCC
Small 6
non-
cleaved
FCC
Small 0
non-
cleaved
FCC
Small 55
non-
cleaved
FCC
Immuno- 4
blastic
sarcoma
Immuno- 15X
blastic
sarcoma
Immuno- 40
blastic
sarcoma
Plasma- 48$
cytoid
lympho-
cytic
Histio- 76
cytic
VWUZ Histiocytic Histio-
cytic
B cells
A
FITC antibody staining Rosettes
C3 Fcy MAG
32 7 nd
37
27
26
0
26
75
12
9
24
11
34
73
74
10
16
0
71
11
41
28
63
83
nd
nd
63
76
79
nd
66
45
Lb y
50
ia
1
4
E
I.
t
f
7
n
12 78 0 60
Brightnesst y CX IL 8 K A
+++ 14 0 50 0 0 52
47 +++
84 ++
95 + -
80 ++
31 ++
84 ++
78 ++
7 ++
id nd
28 +
0 0
nd
1
HO
0
4
0
70
nd
nd
0
0
nd
1
0
0
1
4
0
nd
nd
0
0
nd
81
96
80
22
77
0
nd
nd
8
0
nd
2
0
0
17
nd
0
nd
nd
2
0
nd
0
96
80
9
81
50
nd
nd
24
0
nd
76
0
0
25
0
54
nd
nd
1
0
Key to Tables III and IV Lymphoma Clas8ification (Rappaport*)
WDDL = well differentiated diffuse lymphoma
MWDDL = moderately well differentiated diffuse lymphoma
IDDL = intermediate differentiated diffuse lymphoma
WDNL = well differentiated nodular lymphoma
MHLL (N or D) = mixed histiocytic/lymphocytic lymphoma (nodular or diffuse)
UDDL = undifferentiated diffuse lymphoma
UDSL = undifferentiated stem cell lymphoma
FCC = follicular centre cell (Lukes and Collins)
o results expressed as % +ve cells.
$ intensity of immunoglobulin staining + weak
+ + moderately bright
+ + + bright
nd - not done
nr = tumour cells not recognizable
x viability 60%.
$ tumour cells dumped: results refer to normal lymphocyte population
number of positive cases t results expressed as: (total cases studied)
A,
'N
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C3 and sheep E rosette cytocentrifuge
preparations, and by relating these to
the histological sections. Small cleaved
lymphoma cells were not easily identified
in cytocentrifuge preparations, and in
these cases the rosetting characteristics of
the tumour cells were deduced from the
monotypic staining data, indicating the
size of the tumour population, and the
number of T cells. The surface and intra-
cellular immunoglobulin staining and Fc y
and C3 receptor characteristics of the
tumour cells, and the results of the serum
and urine immunoglobulin analvsis are
given in Table IV. The cases have been
grouped according to histology.
DISCUSSION
The attempt of new classification
schemes forthe non-Hodgkin'slymphomas
to incorporate concepts of the origin and
function of lymphoma cells is based on a
better understanding of the structure and
function ofnormal lymph nodes and ofthe
morphological transformation of normal
T and B lymphocytes (Lukes and Collins,
1975). It has been suggested that many
non-Hodgkin's lymphomas are malignant
proliferations of B lymphocytes at various
points along an antigen-driven maturation
pathway and that few lymphomas repre-
sent true histiocytic neoplasms (Salmon
and Seligmann, 1974; Gerard-Marchant
et al., 1974; Lukes and Collins, 1975).
Of the 28 cases studied by us, lymphocyte
markers confirmed that 2 lymphomas
were of histiocytic origin, whereas none
were derived from T cells, 2 were unclassi-
fiable and the remainder were B-cell
neoplasms.
Ultrastructural, cytological and func-
tional features of two cases (PUR, WUZ)
indicated a histiocytic origin. In PUR the
tumour cells had no detectable lympho-
cyte markers. In WUZ the tumour cells
had C3 receptors, but the surface immuno-
globulin detected on these cells by the
MAG test was not seen by direct immuno-
fluorescence and may represent absorbed
immunoglobulin.
The other lymphomas were classifiable
on the basis of Lukes and Collins' scheme
as lymphoid in origin. However, 2 of
these (SHE, STE) did not exhibit mono-
typic surface or intracellular immuno-
globulin consistent with B-lymphoid
origin. Both these immunoblastic sar-
comas differed significantly in surface
receptor expression. One (STE) lacked all
receptors investigated and presented as a
null-cell lymphoma. SHE tumour cells
expressed both Fcy and C3 receptors, but
the surface immunoglobulin findings
(IgGKA) suggested an extrinsic rather than
intrinsic origin. The differing surface
receptor patterns on these two lymphoma
cases with cytological similarity to a
third case (SIR), for which lymphocytic
markers confirmed a B-lymphoid origin,
illustrates the heterogeneity within lym-
phomas of this type classified on morpho-
logical criteria alone.
The remaining 24 lymphomas were
considered to be of B-lymphocyte origin
by virtue of monotypic surface immuno-
globulin or by monotypic intracellular
immunoglobulin. The class and intensity
of surface-immunoglobulin staining varied
between lymphomas of different histo-
logical types. t heavy chain was identified
in 21 cases, y in 1 and of in 1. The surface
light chain was K in 17 cases and A in 6.
This ratio of K/A light-chain-bearing
tumours and the predominance of u
heavy-chain-bearing tumours reflects the
expression of light and heavy chains in
normal lymph nodes. 8 heavy chains were
found together with pu chains on the
tumour cells of 6/17 cases in which 8 was
investigated. Allofthe8-bearing caseswere
well differentiated diffuse lymphocytic
lymphomas. 8 did not occur on the same
number of cells as ,u, but crossover
indicated that many tumour cells from
these cases expressed both ,u and 8 heavy
chains. Furthermore, in each case there
was a difference in staining intensity
for p and 8 chains: in only one case
(HOL) was the anti-8 staining brighter
than anti-,u. Although there are too few
cases for general conclusions to be drawn,
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the restriction of s-chain expression to
small lymphocyte non-follicular centre
cell (non-FCC) lymphomas is of con-
siderable interest, and is in conflict with
the findings of others who have demon-
strated 8 on lymphomas outside this
group (Preud'homme et al., 1974; Leech
et al., 1975). In control lymph nodes,
including those with prominent follicular
hyperplasia, most B cells expressed both
surface 8 and y heavy chains.
The intensity of membrane-immuno-
globulin staining varied between lym-
phomas of different types. Variable stain-
ing ranging from strong to weak was
observed in the small, non-FCC group,
the tissue counterpart of CLL, which is
consistent with the patterns of surface
immunoglobulin staining observed in CLL
(unpublished observations). The brightest
surface-immunoglobulin staining group
consisted of cleaved FCC lymphomas.
Compared with this group, the intensity
ofstaining was reduced onundifferentiated
lymphoma cells, and the plasmacytoma
did not exhibit surface immunoglobulin.
The serum immunoglobulin levels did
not show any significant pattern. Presum-
ably, alterations in serum immunoglobulin
are secondary to malignancy, and changes
become increasingly exaggerated during
the course of the disease. However, it was
significant that Bence-Jones protein was
identified in 2/8 cases investigated. One
of these was a small non-FCC lymphoma
and the other a small non-cleaved FCC
lymphoma. Excess cellular production
of light chain, detectable by synthesis
studies, often occurs in all lymphoma
groups before overspill is detected in the
urine (unpublished observation).
C3 and/or Fcy receptors were present
on the tumour cells in the majority
(I19/22) of lymphocytic lymphomas. C3
receptors were expressed in a higher
proportion of cases than Fcy receptors,
reflecting the predominance ofC3-receptor-
bearing lymphocytes in normal lymph
nodes. Tests with unsensitized or IgM-
antibody ox cells were consistently nega-
tive (<50%o cells reacting). Not all tumour
cells in each case expressed these receptors,
and there was variability in the strength
of indicator red-cell attachment. Mitotic
rate and abnormal function of neoplastic
lymphocytes may contribute to this
variability. However, receptors were
absent, or present only weakly, in several
of the undifferentiated lymphomas and
were absent from the plasmacytoma. It
has been suggested that these undifferen-
tiated lymphoma cells may be related to
non-cleaved FCC or immunoblasts, that
is, lymphocytes relatively far advanced
along an antigen-driven maturation path-
way (Lukes and Collins, 1975). A loss or
reduction in surface immunoglobulin, Fc y
and C3 receptors on these lymphoma cells
would therefore be consistent with a loss
or reduction of these receptors during
B-cell maturation (Perkins, Karnovsky
and Unanue, 1972; Nossal and Lewis,
1972; Basten, Warner and Mandel, 1972;
Bianco, Patrick and Nussenzweig, 1970;
Parish and Hayward, 1974).
None of the lymphomas were derived
from T lymphocytes; however, small T
lymphocytes of normal morphology were
present in all but one of the lymphomas
studied, and accounted for, on average,
28% of the extracted cell population.
A higher proportion of T cells was found
in follicular lymphomas (average 45%)
than in diffuse lymphomas (average 24%).
This may be of significance in relation
to the better prognosis of follicular
lymphomascomparedwithdiffusetumours.
We are most grateful to hospitals out-
side the Southampton area, and to the
Mount Vernon Hospital in particular, for
their cooperation in sending fresh biopsy
material. We also acknowledge the
generous financial support of the Cancer
Research Campaign and Leukaemia
Research Fund.
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